Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics
Alternative Names: CHR-3996; Nana-val; Tractinostat; Tractinostat-Viracta-Therapeutics; Valganciclovir/Nanatinostat combination therapy - Viracta Therapeutics; VRx-3996Latest Information Update: 22 Aug 2024
At a glance
- Originator Chroma Therapeutics
- Developer Chroma Therapeutics; Viracta Therapeutics
- Class Amides; Antineoplastics; Antivirals; Hypoxanthines; Pyrimidines; Quinolines; Small molecules
- Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphoma
- Phase I/II Multiple myeloma; Nasopharyngeal cancer; Solid tumours
- Phase I Cancer
- No development reported Gastric cancer; Post-transplant lymphoproliferative disorder
Most Recent Events
- 14 Aug 2024 Viracta Therapeutics announces intention to submit NDA to US FDA for accelerated approval based on interim analysis of the NAVAL-1 trial’s expansion cohort in 2026
- 14 Aug 2024 Viracta Therapeutics plans meeting with US FDA to finalize the proposed RCT design in the second-line treatment of patients with EBV+ PTCL in the first half of 2025
- 14 Aug 2024 Viracta Therapeutics receives productive feedback from meeting with the USFDA